Welcome to our dedicated page for Aethlon Medical SEC filings (Ticker: AEMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aethlon Medical, Inc. (Nasdaq: AEMD) SEC filings page on Stock Titan brings together the company’s U.S. regulatory documents, giving investors direct access to the disclosures that frame its clinical and financial profile. Aethlon is a clinical-stage medical device company based in San Diego, California, focused on developing the investigational Hemopurifier to address unmet needs in oncology and life-threatening infectious diseases.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe Aethlon’s business, risk factors, Hemopurifier development programs, and financial condition. Current reports on Form 8-K provide detail on material events such as public offerings and private placements of common stock and warrants, reverse stock split actions, Nasdaq listing notices and compliance updates, and key clinical and corporate announcements referenced in company press releases.
For those tracking AEMD’s capital structure, registration statements on Form S-1 and related amendments outline the terms of securities offerings, including common stock, pre-funded warrants, and common stock purchase warrants, as well as associated registration rights. These filings explain how many shares and warrants are being registered, exercise prices and durations, and the company’s stated use of proceeds for working capital, clinical trial expenses, research and development, and other corporate purposes.
Stock Titan enhances these filings with AI-powered summaries that highlight key elements of lengthy documents, helping readers quickly identify items such as Hemopurifier development disclosures, Nasdaq listing discussions, and financing terms. Real-time updates from EDGAR ensure that new Aethlon Medical filings appear promptly, while dedicated sections make it easier to locate material 8-Ks, registration statements, and periodic reports relevant to AEMD’s evolving clinical-stage strategy.
Aethlon Medical (NASDAQ:AEMD) filed its Annual Report for the fiscal year ended March 31, 2025.
- Maintains status as a non-accelerated filer & smaller reporting company.
- Implemented a 1-for-8 reverse stock split effective June 6 2025; post-split shares outstanding total 2,585,316.
- Aggregate market value of non-affiliate shares was $6.65 million as of Sept 30 2024 (close $3.73).
- Discloses May 2024 public offering and March 2025 warrant inducement; details appear in Equity & Liquidity sections.
- No indication of being a shell company or well-known seasoned issuer; all Exchange Act filings current.
The filing provides audited FY 2025 financial statements, updated risk factors, new Cybersecurity disclosures and forward-looking statements that may affect future capital raising and regulatory pathways.